Q3 2022 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Third Quarter 2022 Conference Call. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with a brief overview of the quarter and recent developments; Fady Malik, EVP of R&D, will provide updates related to omecamtiv mecarbil; Andrew Callos, EVP and Chief Commercial Officer, will review commercialization planning activities for omecamtiv mecarbil and our specialty cardiology franchise strategy related to aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will provide an update on reldesemtiv; Robert Wong, VP and Chief Accounting Officer, will provide a financial overview of the past quarter; and Ching Jaw SVP and Chief Financial Officer, will discuss our financial outlook and corporate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |